A Study to Assess the Rate of Hospitalization in Participants With Schizophrenia Treated With Antipsychotics (REALAI)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02712463|
Recruitment Status : Completed
First Posted : March 18, 2016
Last Update Posted : May 24, 2016
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||310 participants|
|Official Title:||A Retrospective, Observational Study to Assess the Rate of Hospitalization in Patients With Schizophrenia Treated One Year Before With Oral Antipsychotics and One Year After With Long Acting Injectable Atypical Antipsychotics - REALAI Study|
|Study Start Date :||July 2015|
|Actual Primary Completion Date :||April 2016|
|Actual Study Completion Date :||April 2016|
Participants with Schizophrenia
This is an observational study. Data will be collected from the medical records of participants diagnosed with schizophrenia and who had been on oral antipsychotics for at least one year and thereafter have been switched to Long Acting Injectable atypical antipsychotics for at least one year.
- Percentage of Participants with Hospitalizations in 12 Months Before Initial Long Acting Injectable anti-psychotics (LAI) use [ Time Frame: 12 months before initial LAI use ]Percentage of participants with hospitalizations due to Psychotic relapse of schizophrenia will be reported.
- Percentage of Participants with Hospitalizations in 12 Months After Initial Long Acting Injectable anti-psychotics (LAI) use [ Time Frame: 12 months after initial LAI use ]
- Number of hospitalizations due to Psychotic Relapse of Schizophrenia [ Time Frame: approximately 2 years ]The number of hospitalizations due to Psychotic relapse of schizophrenia will be reported.
- Number of Days of Hospitalization due to Psychotic Relapse of Schizophrenia [ Time Frame: approximately 2 years ]The number of days of hospitalization due to Psychotic relapse of schizophrenia will be reported.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02712463
|Rio De Janeiro, Brazil|
|Sao Jose, Brazil|
|Sao Paulo, Brazil|
|San Pedro Garza García, Mexico|
|Study Director:||Janssen-Cilag Ltd. Clinical Trial||Janssen-Cilag Ltd.|